# AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct00022282/  
OnCo record `nct00022282` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Shark cartilage in Multiple myeloma, run by AEterna Zentaris, completed.

## Summary

AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma is a phase 2 interventional study registered as NCT00022282 by AEterna Zentaris, started 2001-04 and reaching its primary completion in 2007-03. Interventions recorded: shark cartilage extract AE-941. Conditions recorded: Multiple Myeloma and Plasma Cell Neoplasm.

Linked to the technology Shark cartilage because the registry names it ("shark cartilage") among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00022282
- Phase: 2
- Setting: Neovastat (AE-941) in Refractory and Early Relapse Multiple Myeloma Patients
- Sponsor: AEterna Zentaris

## Sources

- ClinicalTrials.gov NCT00022282: https://clinicaltrials.gov/study/NCT00022282

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [Shark cartilage (AE-941, Neovastat)](https://onco.cc/technologies/shark-cartilage/)
- companies: [Aeterna Zentaris](https://onco.cc/companies/aeterna-zentaris/)

---
JSON: https://onco.cc/api/v1/entities/nct00022282.json